Atrial functional MR is not the same as ventricular functional MR
Atrial functional MR is driven by AF, LA enlargement, and mitral annular dilation — not by LV dilation or leaflet tethering. Management priorities and the TEER evaluation pathway differ from ventricular functional MR. COAPT-like HFrEF secondary MR criteria should not be directly extrapolated to atrial functional MR.
A 78-year-old patient has longstanding persistent AF, marked LA enlargement, dyspnea, preserved LVEF of 60%, and moderate-to-severe MR on TTE. The leaflets do not appear primarily degenerative. Is this primary MR? Secondary MR from LV systolic dysfunction? Or a different mechanism? This is the setting where atrial functional MR should be considered.
Key takeaway
Atrial functional MR results mainly from LA enlargement and mitral annular dilation, often related to longstanding AF or HFpEF. It is not primarily caused by papillary muscle displacement or LV systolic dysfunction. LV systolic function may be preserved. Management priorities differ: AF management, rate/rhythm control, volume and filling pressure optimization, BP control, and HFpEF therapy come first. COAPT-like TEER eligibility criteria were developed for HFrEF-type secondary MR and should not be directly applied to atrial functional MR.
Key points
- Atrial functional MR is driven by LA enlargement and mitral annular dilation, often in longstanding AF, HFpEF, or both.
- LVEF may be preserved. Significant MR with LVEF 55–65% and AF should prompt consideration of atrial functional MR.
- The leaflets are often not the primary pathology. Leaflet tethering is mild or absent; annular dilation, annular flattening, and posterior leaflet malcoaptation are central mechanisms.
- First optimize AF management, rate/rhythm control, BP, volume status, filling pressure, and HFpEF therapy.
- COAPT LVEF criteria of 20–50% cannot be directly extrapolated to preserved-EF atrial functional MR.
When to read this
Read this when a patient has significant MR, longstanding AF, a large LA, and preserved or mildly reduced LVEF, and the mechanism does not fit classic primary MR or typical LV-tethering secondary MR.
The pathophysiology of atrial functional MR
In ventricular functional MR, LV dilation displaces the papillary muscles outward and apically. This tethers the leaflets toward the apex and prevents normal coaptation. The initiating problem is the ventricle.
In atrial functional MR, the initiating problem is the atrium. Longstanding AF or HFpEF can enlarge the LA and dilate the mitral annulus. As the annulus widens and flattens, the leaflets must span a larger or less favorable coaptation geometry. Even without primary leaflet disease or major papillary muscle displacement, coaptation may fail and MR develops.
Leaflet tethering in atrial functional MR is mild or absent. The central mechanisms are annular dilation, annular flattening, and posterior leaflet malcoaptation — not apical tethering from papillary muscle displacement.
Why LVEF may be preserved
In ventricular functional MR, HFrEF is often present and LVEF is commonly reduced — often in the 25–40% range. In atrial functional MR, LV systolic function may be preserved.
A patient with LVEF 60%, longstanding AF, marked LA enlargement, and moderate-to-severe MR should prompt consideration of atrial functional MR rather than assuming primary MR or HFrEF-type secondary MR.
Preserved LVEF does not mean low risk. HFpEF, pulmonary hypertension, RV dysfunction, AF rate, and beat-to-beat irregularity may all affect perioperative risk.
Management principles
The first priority is treating the atrial and filling-pressure substrate. Optimize AF rate control. Consider rhythm control, cardioversion, or ablation when appropriate. Manage BP, volume status, and congestion. If HFpEF is present, optimize HFpEF therapy, including SGLT2 inhibitors when appropriate.
Improving rhythm, rate, BP, and volume status may reduce LA and annular stress and improve MR in some patients.
Evidence for TEER or surgical treatment in atrial functional MR is evolving. Valve intervention may be considered in selected patients, but decisions should not be made by applying COAPT-like HFrEF criteria alone. Heart Valve Team evaluation is needed.
Perioperative perspective
For elective noncardiac surgery in a patient with atrial functional MR, MR grade alone is not enough to assess risk.
- Is AF rate controlled?
- Is rhythm control relevant or feasible?
- Is volume status optimized?
- Is filling pressure elevated from HFpEF or diastolic dysfunction?
- Is pulmonary pressure elevated?
- Is RV function preserved?
- Can the patient tolerate perioperative fluid shifts?
Atrial functional MR should be evaluated as part of an AF/HFpEF/pulmonary pressure/right-heart context, not simply as a valve lesion.
Do not default to ventricular functional MR management in this population
The Secondary MR Intervention Navigator branches atrial functional MR to a separate pathway. COAPT-like TEER criteria, HFrEF GDMT algorithms, and LV-centered staging do not automatically apply. Start with AF management, rate/rhythm control, volume and filling pressure optimization, BP control, and HFpEF therapy. If symptoms persist, MR remains significant, and valve anatomy is suitable, TEER or surgery may be discussed by the Heart Valve Team.
Apply this in practice
Use the Secondary MR Intervention Navigator and select 'atrial functional MR' as the mechanism.
Secondary MR Intervention Navigator